On Time, On Target
News Mar 02, 2015
By measuring how vigorously tumor cells turn on “self-destruct” signals when exposed to different cancer drugs, a novel lab test can predict within less than 24 hours which agent is most likely to work against a particular tumor, according to research from Harvard Medical School and Dana-Farber Cancer Institute.
The scientists say this technique could lead to more reliable and rapid tools for “personalizing” cancer treatments than those that are now available. Clinical testing has already begun.
A team led by oncologist Anthony Letai, HMS associate professor of medicine at Dana-Farber, reported in the February 26, 2015, online edition of the journal Cell that the test consistently predicted the “winner” among many drugs tested against a wide variety of cancer cells in the laboratory. In most cases, the answer emerged 16 hours after the anticancer compounds were mixed with tumor cells.
“We demonstrated that [the test] can be exploited to select among many therapies the one that is best for a single tumor,” the researchers wrote. “We also demonstrated that it can select among many patients those [who] are most likely to respond to a single therapy.”
The technique, dynamic BH3 profiling, or DBP, is designed to detect the earliest signs that a cancer cell treated with a drug is beginning to destroy itself through apoptosis, a natural quality-control process that rids the body of unneeded or dangerously abnormal cells.
Cancer cells can survive by blocking the molecular signals that trigger apoptosis. Most chemotherapy treatments work by inducing a wave of “pro-death” signals in cancer cells to overcome the cells’ survival signals. The death process may take several days, but with the DBP test, scientists can identify which drug or drug combination has most effectively jump-started pro-death signaling.
“This new technique represents a completely novel approach to precision medicine because we can test possible treatment directly on patient samples to guide cancer therapy,” said Joan Montero, HMS research fellow in medicine in Dana-Farber’s Letai lab and the first author on the report.
The test must be performed on living tumor cells that were removed during surgery or a biopsy or were frozen in a manner that leaves the cells viable. It will not work on tumor samples that have been preserved in formalin, the investigators said.
In their research, the scientists exposed cancer cells to a long list of “targeted” drugs that block different overactive signaling pathways that prod cancer cells into unruly growth. The drugs were tested against many different types of cancer cells, including non-small cell lung cancers, breast cancers, colon cancers, leukemia, lymphoma and multiple myeloma.
“Regardless of the pathway inhibited, or what kind of cell the cancer started in, early drug-induced death signaling predicted later cytotoxicity,” said Letai. “We can take an early peek to see if the cancer cell is being pushed toward death. What makes this especially powerful is that we’re not restricted to using one drug at a time, [so] it can test the effectiveness of combinations.”
In an experiment using ovarian cancer cells removed from 16 patients, DBP testing was used to predict which tumors would respond to carboplatin, a standard chemotherapy drug. Patients whose cells responded strongly in the laboratory experienced significantly longer delays before their disease progressed.
A major current thrust of precision cancer medicine is to test a patient’s tumor for DNA mutations that have been found to make the cancer sensitive to certain drugs that target those mutations. This isn’t always successful, and most tumors likely have properties beyond mutations that determine their responsiveness to drugs.
The authors of the new study said the DBP method is potentially more powerful because it tests the cancer drugs of interest directly on cells from the patient’s tumor and quickly determines which drugs can kill the cancer.
Going forward, the investigators plan to test the predictive power of DBP technique on samples from patients entering clinical trials and monitor whether their outcomes correlate with the test results. Once this initial testing is done, they anticipate using DBP in the clinic in the next couple of years.
The research was supported by National Institutes of Health grants R01CA129974, RO1CA135257, P01CA068484, P01CA139980 and U01CA152990.
Superior Pathological Diagnosis Using Transparent TissuesNews
In a new study researchers report CUBIC, a technique including a tissue processing that makes human organs transparent, and provides better assessment of lesions for pathological diagnosis.READ MORE
Agilent Obtains U.S. FDA Approval for GenetiSure Dx Postnatal AssayNews
Agilent Technologies has obtained 510(k) clearance from the FDA for the GenetiSure Dx Postnatal Assay: its first comparative genomic hybridization (CGH) assay for diagnostic use.READ MORE
Endomag Receives CE Mark Approval for Magseed Breast Cancer Localisation TechnologyNews
Endomag can now use Magseed, an accurate marker for surgeons to use during breast cancer removal surgery.READ MORE
Comments | 0 ADD COMMENT
13th Edition of International Conference on Pediatric Gastroenterology
Aug 02 - Aug 04, 2018